On August 5, Hinge Health, Inc. rose 5.09% in regular trading, trading at $82.37/share, with turnover of $25.17 million. The rally was driven by a strong Q2 earnings report released after the prior session's close, featuring revenue that significantly exceeded expectations alongside a substantial upward revision to full-year guidance.

Hinge Health reported Q2 revenue of $212.8 million, up 53% year-over-year and well above the analyst consensus estimate of $201.5 million. Adjusted EPS came in at $0.59, meeting expectations. More importantly, the company raised its full-year revenue guidance to $856 million-$860 million, materially above the Street estimate of $822.2 million. Q3 revenue guidance of $223 million-$225 million also exceeded the $211.5 million consensus. Following the results, Morgan Stanley raised its price target to $117 from $108, maintaining an Overweight rating.

Hinge Health is an AI-driven digital musculoskeletal care platform that delivers end-to-end services from acute injury treatment to post-surgical rehabilitation through wearable devices and clinical teams.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)